Mozambique to launch Papilloma virus vaccine next year
Health authorities in Mozambique will in 2014 begin to administer a vaccine against the human papilloma virus (HPV) responsible for the majority of cases of cervical cancer.
The weekly Sunday paper Domingo reported on Sunday that the immunisation will mainly be financed by GAVI (Global Alliance for Vaccines and Immunisation), a public-private international health partnership.
According to the chief executive officer of GAVI, Dr Seth Berkley, “a vast gap currently exists between girls in rich and poor countries. With GAVI’s programmes we can begin to bridge that gap so that all
girls can be protected against cervical cancer no matter where they are born”.
He added that “by 2020 we hope to reach more than 30 million girls in more than 40 countries. This is a transformational moment for the health of women and girls across the world”.
Worldwide, cervical cancer is the second most common cancer in women with an estimated 529,000 new cases and 275,000 deaths in 2008.
Speaking on behalf of vaccine manufacturer GlaxoSmithKline, Deanna Petersen told journalists that “the vaccine will begin rollout in Mozambique in 2014 and therefore details are still being finalised.
However, access to the vaccine will have a significant impact on health, she added.
According to the Ministry of Health eighty percent of cases of cervical cancer diagnosed in Mozambique are in their terminal stages.